Phase 1, Open-Label, Ophthalmology and Neurology Safety Study of Oral 200 mg TR-701 FA Once Daily for 10 Days in Healthy Adults

Trial Profile

Phase 1, Open-Label, Ophthalmology and Neurology Safety Study of Oral 200 mg TR-701 FA Once Daily for 10 Days in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Tedizolid (Primary)
  • Indications Bacteraemia; Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 15 Nov 2016 Results of this and one other phase 1 study assessing ophthalmologic and neurologic clinical examinations published in the American Journal of Therapeutics.
    • 01 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top